Time filter

Source Type

Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2017-01-18

The present invention relates to a recombinant microorganism expressing avermectin or analogues thereof and construction method thereof, and also relates to a method of producing avermectin or analogues thereof using the recombinant microorganism, and avermectin or analogues thereof obtained using the method. In addition, the present invention further relates to uses of the avermectin or analogues thereof as insecticides. Using the recombinant microorganism of the present invention to produce avermectin or analogues thereof has numerous advantages, for example comprising at least one of the following: good stability, high yield, simple process, environmentally friendly, and greatly saving of production costs.


Patent
Zhejiang Hisun Pharmaceutical Co. and Zhejiang Hisun Chemical Co. | Date: 2017-01-18

A sixteen-membered macrolide compound and use thereof, the compound structure being represented in formula (I), wherein R is CH_(3) or C_(2)H_(5). The present compound has a wide range of application in the preparation of chemicals for preventing and controlling insect pests and mites of agriculture and forestry.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2017-01-11

The present invention relates to novel crystal forms M and N of dabigatran etexilate mesylate and preparation method and uses thereof, wherein the X-Ray powder diffractogram of the crystal form M has characteristic peaks at the following 2 diffraction angles: 5.70.2, 6.20.2, 11.20.2, 12.40.2, 18.20.2, 21.40.2, 21.80.2 and 23.60.2; and the X-Ray powder diffractogram of the crystal form N has characteristic peaks at the following 2 diffraction angles: 6.00.2, 11.80.2, 18.20.2, 21.60.2, 24.40.2, 27.70.2 and 29.70.2. The crystal forms of the present invention have excellent properties in the aspects of leaching time, biological release, chemical stability and processing adaptability.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2016-12-21

The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxybut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powder diffraction (XRPD) spectra, differential scanning calorimetry (DSC) spectra, infrared absorption spectra and so on. Meanwhile, the present invention also provides methods for preparing the crystal forms of the compound of formula A, pharmaceutical compositions and uses thereof.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2016-12-21

The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxybut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powder diffraction (XRPD) spectra, differential scanning calorimetry (DSC) spectra, infrared absorption spectra and so on. Meanwhile, the present invention also provides methods for preparing the crystal forms of the compound of formula A, pharmaceutical compositions and uses thereof.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2017-05-17

A fidaxomicin purification method, comprising: fermenting Actinoplanes sp. HS-16-20 to generate fermented liquid; conducting solid/liquid separation on the fermented liquid, soaking mycelium in an organic solvent, and filtering to obtain a solution containing fidaxomicin; treating the solution with nanofiltration concentrate, and separating to obtain fidaxomicin crude product; conducting preparative column chromatography on the fidaxomicin crude product, eluting with an acid aqueous solution containing an organic solvent, and separating to obtain the refined fidaxomicin product.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2016-10-26

Disclosed is a pharmaceutical composition comprising adalimumab and a structure stabilizer, wherein the structure stabilizer is selected from sucrose or trehalose, and the pharmaceutical composition has a high stability.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2016-08-24

A bacterial strain of Actinoplanes sp. and an application thereof. The bacterial strain is named Actinoplanes sp.HS-16-20, whose preservation number is CGMCC No.7294. The bacterial strain can generate Fidaxomicin, and Fidaxomicin has an inhibitory effect on various gram positive bacteria pathogens, and in particular, on Clostridium difficile.


Patent
Zhejiang Hisun Pharmaceutical Co. | Date: 2016-09-21

The present invention relates to a disaccharide intermediate and a synthesis method thereof, relates to the chemical pharmaceutical field, and more specifically relates to a method for preparing a disaccharide segment of a key intermediate for chemically synthesizing heparin and heparinoid compounds. Disclosed are a new disaccharide intermediate and three methods for synthesizing the disaccharide intermediate, that is, compounds of a formula (4) and glucopyranose protected by different anomeric carbon are made to react in the presence of an active agent, to obtain the disaccharide intermediate. According to the technical solutions of the present invention, synthetic raw materials are easy to obtain, have a mild reaction condition, and are suitable for industrialized production.


Patent
Zhejiang Hisun Pharmaceutical Co. and Shanghai Institute of Pharmaceutical Industry | Date: 2016-05-04

The present invention provides a key new intermediate (a compound of formula III) of 4-benzyl-1-phenethyl-piperazine-2,6-dione (formula IV compound), a pharmaceutically acceptable salt thereof and a preparation method thereof. The present invention additionally discloses a method for preparing 4-benzyl-1-phenethyl-piperazine-2,6-dione (formula IV compound) from the formula III compound, said method overcoming the shortcomings of current formula IV compound preparation methods, such as low production volumes, low purity, high energy consumption, high costs, and inability to achieve industrialized production, and provides a formula IV compound preparation method which is simple, economical, environmentally-friendly and easy to produce industrially; the reaction solvent of the method is easily recycled and the method can produce the formula IV compound at high production rates and with high purity.

Loading Zhejiang Hisun Pharmaceutical Co. collaborators
Loading Zhejiang Hisun Pharmaceutical Co. collaborators